Jonah Comstock

There was plenty of movement at the top of pharma and biotech in September, with leadership changes spanning some of the industry's biggest names, as well as a broad crop of emerging drug developers.

September brought leadership changes across the businesses providing technology, research, manufacturing, and professional services to the life sciences industry.

Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ALK7.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a document explaining how its regulatory processes will adapt to the era of AI and personalised medicines, to the applause of the pharma industry.

GSK is preparing to cut more than 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels, according to national newspaper L'Echo.

August and September brought leadership changes across healthcare communications, consulting, investment, and industry organisations.

While much of the conversation at LSX in Boston focused on the continued rise of Chinese biotech and the challenges it presents to US firms, some

Revolution Medicines is likely just weeks away from getting EU approval for its oral RAS inhibitor Rasonque as a treatment for pancreatic cancer, after the drug was recommended by the EMA's human medicines committee.

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight management and treatment of type 2 diabetes (T2D).

September's boardroom moves brought seasoned pharma executives, investors, and scientific leaders into new governance and advisory roles across the life sciences sector.